Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.
about
Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Retreatment with bevacizumab i ...... d does not increase morbidity.
@en
Retreatment with bevacizumab i ...... d does not increase morbidity.
@nl
type
label
Retreatment with bevacizumab i ...... d does not increase morbidity.
@en
Retreatment with bevacizumab i ...... d does not increase morbidity.
@nl
prefLabel
Retreatment with bevacizumab i ...... d does not increase morbidity.
@en
Retreatment with bevacizumab i ...... d does not increase morbidity.
@nl
P2093
P2860
P356
P1476
Retreatment with bevacizumab i ...... d does not increase morbidity.
@en
P2093
Alexander B Olawaiye
Ashlee L Smith
Jamie L Lesnock
Jeff F Lin
Joseph L Kelley
Paniti Sukumvanich
Robin A Laskey
Scott D Richard
Thomas C Krivak
Tiffany L Beck
P2860
P304
P356
10.2147/OTT.S57425
P407
P577
2014-03-21T00:00:00Z